nejm semaglutide heart failure Updates in Medicine | 🩺 Oral Cuts CV Risk in High-Risk T2DM – SOUL Trial (NEJM, Mar 2025) 🔗 Original article link in bio 📌 Key Highlights: 🔹 Semaglutide and Cardiovascular Outcomes in

Diabetes Care 41 , 670679 (2018)

Efficacy and Side Effects : Huberman expresses excitement about the efficacy of GLP-1 agonists, acknowledging they promote fat loss but also lead to muscle loss, a concern for individuals who prioritize maintaining muscle mass

Dose escalation should be gradual, following the recommended titration schedule, to minimise gastrointestinal intolerance

(The brand-name GLP-1s arent available as generics because the patents havent expiredNovo Nordisk has its US patent on semaglutide until 2032, and Eli Lilly on tirzepatide, until 2036.) But to be clear, compounders do still operate within a regulatory framework, albeit a less stringent one